 Robert MacLaren
Concepts (505)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 46 | 2025 | 888 | 6.480 |
Why?
| | Intensive Care Units | 41 | 2025 | 915 | 4.540 |
Why?
| | Critical Care | 27 | 2026 | 695 | 4.460 |
Why?
| | Peptic Ulcer | 9 | 2023 | 18 | 3.740 |
Why?
| | Gastrointestinal Hemorrhage | 8 | 2024 | 136 | 3.280 |
Why?
| | Hypnotics and Sedatives | 12 | 2024 | 216 | 3.100 |
Why?
| | Pharmacy Service, Hospital | 10 | 2024 | 81 | 3.000 |
Why?
| | Histamine H2 Antagonists | 9 | 2024 | 23 | 2.860 |
Why?
| | Pharmacists | 11 | 2025 | 240 | 2.770 |
Why?
| | Proton Pump Inhibitors | 9 | 2024 | 109 | 2.740 |
Why?
| | Enteral Nutrition | 13 | 2023 | 217 | 2.670 |
Why?
| | Dexmedetomidine | 9 | 2019 | 44 | 2.540 |
Why?
| | Gastric Emptying | 8 | 2017 | 36 | 1.840 |
Why?
| | Midazolam | 4 | 2024 | 72 | 1.520 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2022 | 187 | 1.450 |
Why?
| | Shock, Septic | 4 | 2022 | 216 | 1.410 |
Why?
| | Epoprostenol | 2 | 2023 | 132 | 1.310 |
Why?
| | Anticoagulants | 12 | 2023 | 729 | 1.280 |
Why?
| | Heparin | 7 | 2023 | 243 | 1.270 |
Why?
| | Professional Role | 5 | 2024 | 159 | 1.160 |
Why?
| | Metoclopramide | 7 | 2010 | 19 | 1.150 |
Why?
| | Vasopressins | 4 | 2022 | 60 | 1.090 |
Why?
| | Sepsis | 7 | 2023 | 643 | 1.030 |
Why?
| | Stress, Physiological | 5 | 2021 | 451 | 1.020 |
Why?
| | Lorazepam | 4 | 2014 | 25 | 1.010 |
Why?
| | Adult | 56 | 2025 | 40489 | 0.980 |
Why?
| | Pneumonia | 5 | 2022 | 629 | 0.970 |
Why?
| | Retrospective Studies | 40 | 2025 | 17149 | 0.950 |
Why?
| | Hemorrhage | 9 | 2021 | 813 | 0.930 |
Why?
| | Humans | 120 | 2026 | 144667 | 0.920 |
Why?
| | Factor VIIa | 5 | 2016 | 43 | 0.900 |
Why?
| | Visual Acuity | 4 | 2024 | 491 | 0.890 |
Why?
| | Thromboembolism | 2 | 2020 | 126 | 0.870 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 144 | 0.870 |
Why?
| | Thrombelastography | 2 | 2023 | 190 | 0.870 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 202 | 0.860 |
Why?
| | Recombinant Proteins | 13 | 2023 | 1363 | 0.860 |
Why?
| | Gastrointestinal Agents | 5 | 2010 | 65 | 0.860 |
Why?
| | Proton Pumps | 2 | 2014 | 8 | 0.850 |
Why?
| | Propofol | 5 | 2019 | 85 | 0.830 |
Why?
| | Ulcer | 1 | 2023 | 37 | 0.780 |
Why?
| | Retinal Degeneration | 2 | 2020 | 39 | 0.770 |
Why?
| | Alcoholism | 2 | 2022 | 813 | 0.710 |
Why?
| | Blood Coagulation Factors | 3 | 2020 | 60 | 0.700 |
Why?
| | Hypotension | 2 | 2022 | 126 | 0.680 |
Why?
| | Hypothermia, Induced | 2 | 2013 | 94 | 0.670 |
Why?
| | Oseltamivir | 1 | 2021 | 15 | 0.670 |
Why?
| | Anti-Ulcer Agents | 3 | 2017 | 12 | 0.670 |
Why?
| | Analgesia | 2 | 2018 | 105 | 0.660 |
Why?
| | Burns | 3 | 2018 | 371 | 0.660 |
Why?
| | Rhodopsin | 1 | 2020 | 11 | 0.640 |
Why?
| | Stress, Psychological | 4 | 2024 | 1148 | 0.640 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2020 | 17 | 0.640 |
Why?
| | Dependovirus | 1 | 2020 | 77 | 0.610 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 248 | 0.600 |
Why?
| | Vision Tests | 1 | 2019 | 22 | 0.600 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 326 | 0.590 |
Why?
| | Vision, Low | 1 | 2019 | 16 | 0.590 |
Why?
| | Esomeprazole | 1 | 2018 | 7 | 0.580 |
Why?
| | Middle Aged | 44 | 2025 | 35971 | 0.570 |
Why?
| | Genetic Vectors | 1 | 2020 | 334 | 0.570 |
Why?
| | Fibrinolytic Agents | 3 | 2016 | 290 | 0.560 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 241 | 0.560 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 388 | 0.550 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 387 | 0.550 |
Why?
| | Fluid Therapy | 3 | 2023 | 148 | 0.550 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 869 | 0.540 |
Why?
| | Genetic Therapy | 1 | 2020 | 313 | 0.540 |
Why?
| | APACHE | 3 | 2010 | 66 | 0.540 |
Why?
| | Phenytoin | 1 | 2017 | 21 | 0.530 |
Why?
| | Erythromycin | 4 | 2010 | 19 | 0.520 |
Why?
| | Albumins | 1 | 2017 | 119 | 0.510 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 196 | 0.500 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 25 | 0.500 |
Why?
| | Ethanol | 3 | 2022 | 627 | 0.500 |
Why?
| | Ketamine | 1 | 2018 | 133 | 0.500 |
Why?
| | Male | 54 | 2025 | 72431 | 0.490 |
Why?
| | Plasma | 2 | 2016 | 223 | 0.490 |
Why?
| | Anticonvulsants | 2 | 2017 | 242 | 0.450 |
Why?
| | Blood Coagulation | 2 | 2007 | 268 | 0.440 |
Why?
| | Aged | 29 | 2025 | 25955 | 0.440 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2015 | 17 | 0.440 |
Why?
| | Partial Thromboplastin Time | 4 | 2023 | 52 | 0.440 |
Why?
| | Female | 51 | 2025 | 78304 | 0.440 |
Why?
| | Hydrocortisone | 1 | 2017 | 297 | 0.440 |
Why?
| | Nitric Oxide | 1 | 2020 | 894 | 0.440 |
Why?
| | Acetaminophen | 5 | 2010 | 265 | 0.440 |
Why?
| | Nerve Growth Factor | 1 | 2015 | 34 | 0.440 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 28 | 0.430 |
Why?
| | Influenza, Human | 1 | 2021 | 618 | 0.430 |
Why?
| | Community-Acquired Infections | 2 | 2014 | 175 | 0.430 |
Why?
| | Stomach Diseases | 2 | 2011 | 20 | 0.420 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 732 | 0.420 |
Why?
| | Epinephrine | 1 | 2015 | 154 | 0.410 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 151 | 0.400 |
Why?
| | Delphi Technique | 2 | 2026 | 330 | 0.400 |
Why?
| | Antifibrinolytic Agents | 2 | 2007 | 63 | 0.400 |
Why?
| | Erythropoietin | 2 | 2005 | 100 | 0.400 |
Why?
| | Prospective Studies | 15 | 2025 | 7994 | 0.400 |
Why?
| | Polyvinyl Chloride | 1 | 2013 | 12 | 0.400 |
Why?
| | Voriconazole | 3 | 2019 | 21 | 0.380 |
Why?
| | Hemodynamics | 2 | 2019 | 1113 | 0.380 |
Why?
| | Hippocampus | 1 | 2018 | 966 | 0.380 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1742 | 0.380 |
Why?
| | Pain | 1 | 2018 | 785 | 0.370 |
Why?
| | Sodium Chloride | 1 | 2013 | 142 | 0.370 |
Why?
| | Drug Monitoring | 3 | 2017 | 396 | 0.360 |
Why?
| | Cohort Studies | 9 | 2025 | 5957 | 0.350 |
Why?
| | Vancomycin | 2 | 2025 | 94 | 0.350 |
Why?
| | Drug Resistance | 2 | 2011 | 145 | 0.350 |
Why?
| | Cross Infection | 4 | 2008 | 263 | 0.350 |
Why?
| | Mental Recall | 1 | 2013 | 222 | 0.350 |
Why?
| | Gastrointestinal Hormones | 1 | 2011 | 5 | 0.350 |
Why?
| | Hirudins | 4 | 2023 | 51 | 0.340 |
Why?
| | Ghrelin | 1 | 2011 | 42 | 0.340 |
Why?
| | Pseudomonas Infections | 4 | 2010 | 230 | 0.340 |
Why?
| | Double-Blind Method | 7 | 2020 | 2033 | 0.340 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 1928 | 0.340 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2023 | 36 | 0.340 |
Why?
| | Cisapride | 2 | 2001 | 5 | 0.330 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 26 | 0.330 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6041 | 0.320 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 771 | 0.320 |
Why?
| | Coagulants | 2 | 2008 | 19 | 0.320 |
Why?
| | Infusions, Intravenous | 6 | 2016 | 422 | 0.320 |
Why?
| | Factor VII | 2 | 2007 | 24 | 0.320 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 51 | 0.320 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2010 | 125 | 0.310 |
Why?
| | Factor Xa | 2 | 2021 | 34 | 0.310 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.310 |
Why?
| | Tachyphylaxis | 1 | 2009 | 4 | 0.310 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.310 |
Why?
| | Drug Therapy, Combination | 6 | 2017 | 1044 | 0.310 |
Why?
| | Antiemetics | 3 | 2010 | 48 | 0.300 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 199 | 0.300 |
Why?
| | Protein C | 1 | 2010 | 53 | 0.300 |
Why?
| | Mutation | 2 | 2020 | 4081 | 0.300 |
Why?
| | Factor Xa Inhibitors | 2 | 2023 | 187 | 0.300 |
Why?
| | Heart Arrest | 1 | 2013 | 406 | 0.300 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 19 | 0.300 |
Why?
| | Treatment Outcome | 14 | 2024 | 11735 | 0.290 |
Why?
| | International Normalized Ratio | 2 | 2016 | 52 | 0.290 |
Why?
| | Pseudomonas aeruginosa | 4 | 2010 | 391 | 0.280 |
Why?
| | Hemofiltration | 3 | 2017 | 24 | 0.280 |
Why?
| | Bradycardia | 3 | 2021 | 61 | 0.280 |
Why?
| | Respiration, Artificial | 6 | 2019 | 710 | 0.280 |
Why?
| | Central Serous Chorioretinopathy | 2 | 2020 | 4 | 0.280 |
Why?
| | Immune System | 1 | 2009 | 178 | 0.270 |
Why?
| | Lung Diseases | 2 | 2007 | 781 | 0.270 |
Why?
| | Attitude of Health Personnel | 2 | 2014 | 1180 | 0.270 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 81 | 0.270 |
Why?
| | Antifungal Agents | 3 | 2019 | 150 | 0.270 |
Why?
| | Photochemotherapy | 2 | 2020 | 39 | 0.270 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2024 | 580 | 0.270 |
Why?
| | Nursing Audit | 1 | 2007 | 4 | 0.260 |
Why?
| | Peptide Fragments | 3 | 2023 | 691 | 0.260 |
Why?
| | Forms and Records Control | 1 | 2007 | 20 | 0.260 |
Why?
| | Hemostatics | 1 | 2007 | 60 | 0.250 |
Why?
| | Risk Management | 1 | 2007 | 83 | 0.250 |
Why?
| | Triazoles | 2 | 2019 | 184 | 0.250 |
Why?
| | Physicians | 2 | 2013 | 949 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 565 | 0.250 |
Why?
| | Bacterial Infections | 1 | 2008 | 247 | 0.240 |
Why?
| | Dopamine Antagonists | 2 | 2008 | 25 | 0.240 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2014 | 562 | 0.240 |
Why?
| | Clinical Pharmacy Information Systems | 1 | 2006 | 5 | 0.240 |
Why?
| | Glutamine | 1 | 2007 | 108 | 0.240 |
Why?
| | Respiration | 1 | 2007 | 206 | 0.240 |
Why?
| | Models, Economic | 1 | 2006 | 61 | 0.240 |
Why?
| | Factor VII Deficiency | 1 | 2005 | 5 | 0.230 |
Why?
| | Cystatin C | 1 | 2025 | 66 | 0.230 |
Why?
| | Anesthetics | 1 | 2007 | 99 | 0.230 |
Why?
| | Anesthesia | 1 | 2009 | 258 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1360 | 0.220 |
Why?
| | Fentanyl | 3 | 2018 | 127 | 0.220 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 81 | 0.220 |
Why?
| | Common Data Elements | 1 | 2025 | 17 | 0.220 |
Why?
| | Analgesics, Opioid | 3 | 2018 | 1142 | 0.210 |
Why?
| | Risk Factors | 9 | 2023 | 10796 | 0.210 |
Why?
| | Intravitreal Injections | 1 | 2024 | 71 | 0.210 |
Why?
| | Aged, 80 and over | 9 | 2024 | 8284 | 0.210 |
Why?
| | Macular Edema | 1 | 2024 | 49 | 0.210 |
Why?
| | Clinical Trials as Topic | 4 | 2017 | 1056 | 0.200 |
Why?
| | Drug Interactions | 2 | 2023 | 401 | 0.200 |
Why?
| | Antidotes | 2 | 2016 | 145 | 0.200 |
Why?
| | Creatinine | 1 | 2025 | 509 | 0.200 |
Why?
| | Regression Analysis | 3 | 2017 | 998 | 0.200 |
Why?
| | Anemia | 1 | 2005 | 189 | 0.190 |
Why?
| | Time Factors | 10 | 2018 | 7140 | 0.190 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.190 |
Why?
| | Clostridium Infections | 2 | 2014 | 74 | 0.190 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 43 | 0.190 |
Why?
| | Cross-Over Studies | 3 | 2020 | 605 | 0.190 |
Why?
| | Angiogenesis Inhibitors | 1 | 2024 | 238 | 0.190 |
Why?
| | Biological Availability | 1 | 2023 | 143 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 226 | 0.190 |
Why?
| | Microbial Sensitivity Tests | 3 | 2018 | 373 | 0.180 |
Why?
| | United States | 9 | 2024 | 16018 | 0.180 |
Why?
| | Warfarin | 2 | 2007 | 173 | 0.180 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2117 | 0.180 |
Why?
| | Antacids | 1 | 2001 | 16 | 0.180 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 764 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 550 | 0.180 |
Why?
| | Minnesota | 1 | 2022 | 170 | 0.180 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 99 | 0.170 |
Why?
| | Colorado | 7 | 2017 | 4558 | 0.170 |
Why?
| | Research Design | 2 | 2026 | 1129 | 0.170 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1209 | 0.170 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 242 | 0.170 |
Why?
| | Health Care Costs | 1 | 2005 | 425 | 0.170 |
Why?
| | Norepinephrine | 1 | 2022 | 196 | 0.170 |
Why?
| | Vitamin K 1 | 1 | 2001 | 1 | 0.170 |
Why?
| | Prothrombin | 1 | 2021 | 24 | 0.170 |
Why?
| | Stomach Ulcer | 2 | 2019 | 12 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 170 | 0.170 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2001 | 33 | 0.170 |
Why?
| | United Kingdom | 2 | 2019 | 337 | 0.170 |
Why?
| | Incidence | 3 | 2022 | 2892 | 0.160 |
Why?
| | Statistics, Nonparametric | 3 | 2016 | 427 | 0.160 |
Why?
| | Catheters | 1 | 2021 | 75 | 0.160 |
Why?
| | Light Coagulation | 1 | 2020 | 10 | 0.160 |
Why?
| | Gene Knock-In Techniques | 1 | 2020 | 60 | 0.160 |
Why?
| | Decision Support Techniques | 3 | 2014 | 461 | 0.160 |
Why?
| | Retinitis Pigmentosa | 1 | 2019 | 20 | 0.150 |
Why?
| | Area Under Curve | 3 | 2014 | 329 | 0.150 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 161 | 0.150 |
Why?
| | Resuscitation | 1 | 2023 | 310 | 0.150 |
Why?
| | Inflammation | 1 | 2011 | 2870 | 0.150 |
Why?
| | Length of Stay | 4 | 2014 | 1339 | 0.150 |
Why?
| | Ischemia | 1 | 2023 | 422 | 0.150 |
Why?
| | Photosensitizing Agents | 2 | 2020 | 41 | 0.150 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 480 | 0.150 |
Why?
| | Electric Stimulation Therapy | 1 | 2019 | 62 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 820 | 0.150 |
Why?
| | Refraction, Ocular | 1 | 2019 | 47 | 0.150 |
Why?
| | Retinal Pigment Epithelium | 1 | 2019 | 79 | 0.140 |
Why?
| | Biometry | 1 | 2019 | 66 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2019 | 0.140 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 78 | 0.140 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4539 | 0.140 |
Why?
| | Restraint, Physical | 1 | 2018 | 75 | 0.140 |
Why?
| | Administration, Inhalation | 1 | 2020 | 570 | 0.140 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 190 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 118 | 0.140 |
Why?
| | Hospital Costs | 2 | 2009 | 125 | 0.140 |
Why?
| | Vasoconstriction | 2 | 2023 | 216 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2025 | 483 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2022 | 707 | 0.130 |
Why?
| | Nitriles | 1 | 2019 | 205 | 0.130 |
Why?
| | RNA, Bacterial | 1 | 2018 | 193 | 0.130 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1997 | 29 | 0.130 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 15 | 0.130 |
Why?
| | Oxygen | 1 | 2023 | 984 | 0.130 |
Why?
| | Critical Care Nursing | 1 | 2018 | 49 | 0.130 |
Why?
| | Pharmacoepidemiology | 2 | 2014 | 22 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 146 | 0.130 |
Why?
| | Anesthetics, Intravenous | 1 | 1997 | 69 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5870 | 0.130 |
Why?
| | Sucralfate | 1 | 2017 | 5 | 0.130 |
Why?
| | Piracetam | 1 | 2017 | 14 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2018 | 120 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 129 | 0.130 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 638 | 0.130 |
Why?
| | Drug Compounding | 2 | 2017 | 107 | 0.120 |
Why?
| | Retina | 1 | 2019 | 319 | 0.120 |
Why?
| | Drug Therapy | 1 | 2017 | 80 | 0.120 |
Why?
| | Administration, Oral | 5 | 2017 | 851 | 0.120 |
Why?
| | Nitroprusside | 1 | 2016 | 71 | 0.120 |
Why?
| | Thiocyanates | 1 | 2016 | 27 | 0.120 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.120 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 101 | 0.120 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2019 | 269 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2025 | 960 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 564 | 0.120 |
Why?
| | Analgesics | 1 | 2018 | 232 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.110 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 5 | 0.110 |
Why?
| | Placebo Effect | 1 | 2015 | 25 | 0.110 |
Why?
| | Academic Medical Centers | 3 | 2019 | 545 | 0.110 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2184 | 0.110 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 32 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 765 | 0.110 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 324 | 0.110 |
Why?
| | Methanol | 1 | 2015 | 45 | 0.110 |
Why?
| | Thrombosis | 1 | 2019 | 396 | 0.110 |
Why?
| | Program Development | 1 | 2017 | 368 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1537 | 0.110 |
Why?
| | Pyridines | 1 | 2019 | 603 | 0.110 |
Why?
| | Treatment Failure | 2 | 2020 | 365 | 0.110 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2014 | 15 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 329 | 0.100 |
Why?
| | Cardiopulmonary Bypass | 1 | 2016 | 217 | 0.100 |
Why?
| | Pain Management | 1 | 2018 | 410 | 0.100 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1569 | 0.100 |
Why?
| | Acute Disease | 3 | 2008 | 1029 | 0.100 |
Why?
| | Shivering | 1 | 2013 | 5 | 0.100 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Osmotic Pressure | 1 | 2014 | 41 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2018 | 886 | 0.100 |
Why?
| | Gene Expression | 1 | 2018 | 1476 | 0.100 |
Why?
| | Laser Therapy | 1 | 2015 | 140 | 0.100 |
Why?
| | Tomography, Optical Coherence | 3 | 2024 | 270 | 0.100 |
Why?
| | Consensus | 2 | 2026 | 475 | 0.100 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 58 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 332 | 0.100 |
Why?
| | Neurologic Examination | 1 | 2013 | 132 | 0.100 |
Why?
| | Thrombocytopenia | 3 | 2018 | 202 | 0.100 |
Why?
| | Liver Diseases | 1 | 2016 | 304 | 0.100 |
Why?
| | Drug Storage | 1 | 2013 | 53 | 0.100 |
Why?
| | Benzodiazepines | 1 | 2014 | 168 | 0.100 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2013 | 127 | 0.100 |
Why?
| | Microphthalmos | 1 | 2013 | 2 | 0.100 |
Why?
| | Drug Packaging | 1 | 2013 | 41 | 0.100 |
Why?
| | Hemostasis | 2 | 2019 | 98 | 0.100 |
Why?
| | Medicare | 2 | 2009 | 899 | 0.100 |
Why?
| | Drug Stability | 1 | 2013 | 169 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 179 | 0.090 |
Why?
| | Injections | 1 | 2013 | 197 | 0.090 |
Why?
| | Health Care Surveys | 1 | 2014 | 537 | 0.090 |
Why?
| | Lens Implantation, Intraocular | 1 | 2013 | 80 | 0.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 259 | 0.090 |
Why?
| | Canada | 3 | 2017 | 432 | 0.090 |
Why?
| | Propensity Score | 1 | 2014 | 373 | 0.090 |
Why?
| | Motilin | 1 | 2011 | 1 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 531 | 0.090 |
Why?
| | Cholecystokinin | 1 | 2011 | 15 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.080 |
Why?
| | Phacoemulsification | 1 | 2013 | 123 | 0.080 |
Why?
| | Societies, Pharmaceutical | 2 | 2020 | 14 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2015 | 465 | 0.080 |
Why?
| | Animals | 5 | 2020 | 37948 | 0.080 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 779 | 0.080 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.080 |
Why?
| | RNA, Messenger | 1 | 2018 | 2815 | 0.080 |
Why?
| | Intraoperative Complications | 2 | 2013 | 157 | 0.080 |
Why?
| | Adolescent | 8 | 2019 | 22409 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 712 | 0.080 |
Why?
| | Lactoferrin | 1 | 2010 | 36 | 0.080 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.080 |
Why?
| | Hospitals, University | 2 | 2008 | 176 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2922 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5967 | 0.070 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 119 | 0.070 |
Why?
| | Imipenem | 2 | 2010 | 16 | 0.070 |
Why?
| | Databases, Factual | 2 | 2018 | 1494 | 0.070 |
Why?
| | Observer Variation | 1 | 2010 | 355 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 597 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2013 | 479 | 0.070 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 137 | 0.070 |
Why?
| | Diagnostic Errors | 1 | 2010 | 177 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5414 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 368 | 0.070 |
Why?
| | Risk Assessment | 2 | 2014 | 3729 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1886 | 0.070 |
Why?
| | Patient Care Team | 1 | 2013 | 690 | 0.070 |
Why?
| | Vitamin K | 1 | 2007 | 45 | 0.060 |
Why?
| | Blood Pressure | 2 | 2004 | 1766 | 0.060 |
Why?
| | Quality Improvement | 3 | 2020 | 1287 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1766 | 0.060 |
Why?
| | Databases as Topic | 1 | 2007 | 71 | 0.060 |
Why?
| | Magnesium | 1 | 2007 | 155 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 98 | 0.060 |
Why?
| | Potassium | 1 | 2007 | 152 | 0.060 |
Why?
| | Cost Control | 1 | 2006 | 37 | 0.060 |
Why?
| | Burn Units | 1 | 2007 | 41 | 0.060 |
Why?
| | Cellulitis | 1 | 2007 | 53 | 0.060 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 120 | 0.060 |
Why?
| | Biomarkers | 2 | 2015 | 4261 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1207 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 512 | 0.060 |
Why?
| | Societies, Medical | 2 | 2020 | 890 | 0.060 |
Why?
| | Anxiety | 1 | 2013 | 1122 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3414 | 0.060 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.060 |
Why?
| | Pipecolic Acids | 1 | 2005 | 24 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 164 | 0.060 |
Why?
| | Half-Life | 1 | 2025 | 152 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2350 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 427 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.060 |
Why?
| | Octreotide | 1 | 2005 | 23 | 0.060 |
Why?
| | Time and Motion Studies | 1 | 2025 | 28 | 0.060 |
Why?
| | Ranibizumab | 1 | 2024 | 21 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2005 | 221 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2005 | 122 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 104 | 0.050 |
Why?
| | Ceftazidime | 1 | 2004 | 7 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2014 | 3603 | 0.050 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 10 | 0.050 |
Why?
| | Mice | 2 | 2020 | 18261 | 0.050 |
Why?
| | Intraocular Pressure | 2 | 2019 | 326 | 0.050 |
Why?
| | Ciprofloxacin | 1 | 2004 | 31 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 63 | 0.050 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 46 | 0.050 |
Why?
| | Tobramycin | 1 | 2004 | 59 | 0.050 |
Why?
| | Urine | 1 | 2004 | 64 | 0.050 |
Why?
| | Bevacizumab | 1 | 2024 | 168 | 0.050 |
Why?
| | Wet Macular Degeneration | 1 | 2024 | 58 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 119 | 0.050 |
Why?
| | Depression | 1 | 2013 | 1561 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 143 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2104 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2873 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1811 | 0.050 |
Why?
| | Skin Diseases | 1 | 2004 | 151 | 0.050 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2009 | 826 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3329 | 0.040 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 113 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2007 | 1033 | 0.040 |
Why?
| | Chronic Disease | 2 | 2020 | 1810 | 0.040 |
Why?
| | Hypertension | 1 | 2010 | 1262 | 0.040 |
Why?
| | Hospitals | 1 | 2006 | 729 | 0.040 |
Why?
| | Gastrointestinal Motility | 1 | 2000 | 29 | 0.040 |
Why?
| | Gastric Mucosa | 1 | 2000 | 52 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 14122 | 0.040 |
Why?
| | Subretinal Fluid | 1 | 2020 | 1 | 0.040 |
Why?
| | Stomach | 1 | 2000 | 109 | 0.040 |
Why?
| | Lasers, Semiconductor | 1 | 2020 | 11 | 0.040 |
Why?
| | Therapeutic Index | 1 | 2020 | 3 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2020 | 42 | 0.040 |
Why?
| | Heart Rate | 1 | 2004 | 853 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 62 | 0.040 |
Why?
| | Methadone | 1 | 2001 | 122 | 0.040 |
Why?
| | Coloring Agents | 1 | 2020 | 91 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2025 | 692 | 0.040 |
Why?
| | Cost Savings | 1 | 2000 | 85 | 0.040 |
Why?
| | Electroretinography | 1 | 2019 | 50 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 524 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 193 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2000 | 103 | 0.040 |
Why?
| | Causality | 1 | 2019 | 126 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 190 | 0.040 |
Why?
| | Linear Models | 1 | 2001 | 845 | 0.030 |
Why?
| | Nausea | 1 | 1998 | 112 | 0.030 |
Why?
| | Data Collection | 1 | 2001 | 635 | 0.030 |
Why?
| | Equipment Design | 1 | 2019 | 527 | 0.030 |
Why?
| | Child | 2 | 2017 | 22600 | 0.030 |
Why?
| | Vomiting | 1 | 1998 | 131 | 0.030 |
Why?
| | Parenteral Nutrition, Total | 1 | 1997 | 30 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 167 | 0.030 |
Why?
| | New Zealand | 1 | 2017 | 54 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 170 | 0.030 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2019 | 247 | 0.030 |
Why?
| | Australia | 1 | 2017 | 287 | 0.030 |
Why?
| | Netherlands | 1 | 2015 | 82 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 221 | 0.030 |
Why?
| | Quality of Life | 2 | 2020 | 3183 | 0.030 |
Why?
| | Vision, Ocular | 1 | 2015 | 47 | 0.030 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 53 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 408 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2007 | 2325 | 0.030 |
Why?
| | Eye Proteins | 1 | 2014 | 85 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 81 | 0.030 |
Why?
| | Crohn Disease | 1 | 1997 | 259 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 282 | 0.030 |
Why?
| | Acidosis | 1 | 2015 | 105 | 0.030 |
Why?
| | Retinal Detachment | 1 | 2014 | 73 | 0.020 |
Why?
| | Axial Length, Eye | 1 | 2013 | 16 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 427 | 0.020 |
Why?
| | Rats | 1 | 2001 | 5570 | 0.020 |
Why?
| | Seizures | 1 | 2017 | 477 | 0.020 |
Why?
| | Tonometry, Ocular | 1 | 2013 | 103 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 618 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2114 | 0.020 |
Why?
| | Risk | 1 | 2014 | 911 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 715 | 0.020 |
Why?
| | Genes, Regulator | 1 | 2010 | 35 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 69 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1076 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 324 | 0.020 |
Why?
| | Microcirculation | 1 | 2010 | 141 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1847 | 0.020 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 167 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 287 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1251 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2754 | 0.020 |
Why?
| | Drug Costs | 1 | 2008 | 117 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2137 | 0.020 |
Why?
| | Thienamycins | 1 | 2005 | 3 | 0.010 |
Why?
| | Polymyxin B | 1 | 2005 | 21 | 0.010 |
Why?
| | Inpatients | 1 | 2010 | 547 | 0.010 |
Why?
| | Colistin | 1 | 2005 | 10 | 0.010 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 5 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 98 | 0.010 |
Why?
| | Platelet Activation | 1 | 2005 | 98 | 0.010 |
Why?
| | Arginine | 1 | 2005 | 238 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 73 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2446 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2010 | 864 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2008 | 586 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1447 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 2003 | 71 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2009 | 709 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1844 | 0.010 |
Why?
| | Transcription Factors | 1 | 2010 | 1726 | 0.010 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 609 | 0.010 |
Why?
| | Sulfonamides | 1 | 2005 | 579 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 484 | 0.010 |
Why?
| | Liver | 1 | 2010 | 1889 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2013 | 2950 | 0.010 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2001 | 288 | 0.010 |
Why?
|
|
MacLaren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|